Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2‐positive breast cancer receiving chemotherapy with or without trastuzumab: Results from North Central Cancer Treatment Group adjuvant trial N9831
Moreno‐Aspitia, Alvaro, Hillman, David W., Dyar, Stephen H., Tenner, Kathleen S., Gralow, Julie, Kaufman, Peter A., Davidson, Nancy E., Lafky, Jacqueline M., Reinholz, Monica M., Lingle, Wilma L., Kutteh, Leila A., Carney, Walter P., Dueck, Amylou C., Perez, Edith A.
Published in Cancer (01.08.2013)
Published in Cancer (01.08.2013)
Get full text
Journal Article